Viridian Therapeutics, Inc.
VRDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001590750
In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Viridian Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 39 | 1 | 55 | +17 |
| Shares | 13.6M | 75.0K | 23.3M | +9.73M (+72.0%) |
| Value | $223.7M | $1.23M | $459.8M | +$237.4M (+106.7%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (20)
Institutions that held Viridian Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Deep Track Capital, LP | 1,336,690 | $26.4M | 1.95% |
| TCG Crossover Management, LLC | 1,314,000 | $26.0M | 12.16% |
| Avidity Partners Management LP | 1,278,261 | $25.3M | 0.54% |
| Paradigm Biocapital Advisors LP | 1,209,051 | $23.9M | 6.83% |
| Citadel Advisors LLC | 943,340 | $18.6M | 0.02% |
| Kynam Capital Management, LP | 287,934 | $5.69M | 3.04% |
| Woodline Partners LP | 257,670 | $5.09M | 0.07% |
| Atlas Venture Life Science Advisors, LLC | 90,072 | $1.78M | 0.16% |
| Soleus Capital Management, L.P. | 90,000 | $1.78M | 0.24% |
| Marshall Wace, LLP | 88,405 | $1.75M | 0.00% |
| ExodusPoint Capital Management, LP | 76,757 | $1.52M | 0.02% |
| Endurant Capital Management LP | 67,450 | $1.33M | 0.36% |
| 683 Capital Management, LLC | 21,628 | $428.0K | 0.02% |
| Atom Investors LP | 18,884 | $373.0K | 0.10% |
| Qube Research & Technologies Ltd | 17,000 | $336.0K | 0.00% |
| Citigroup Inc | 14,884 | $294.0K | 0.00% |
| JPMorgan Chase & Co | 13,033 | $258.0K | 0.00% |
| PDT Partners, LLC | 12,615 | $249.0K | 0.02% |
| Sender Co & Partners, Inc. | 12,216 | $242.0K | 0.15% |
| Tower Research Capital LLC (TRC) | 1 | $0 | 0.00% |
Sold out (3)
Institutions that held Viridian Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Logos Global Management LP | 1,500,000 | $24.7M |
| Walleye Trading LLC | 7,500 | $123.0K |
| Ra Capital Management, L.P. | 1,034 | $17.0K |
Not filed for Q4 2021 yet (1)
Institutions that held Viridian Therapeutics, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Marshall Wace North America L.P. | 75,000 | $1.23M |